Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.67M | 951.00K | 1.12M | 1.29M | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.89M | 1.19M | 1.41M | 1.54M | 1.49M |
| Operating Income | -53.89M | -1.19M | -1.41M | -1.54M | -1.49M |
| Income Before Tax | -55.21M | -1.67M | -1.95M | -1.95M | -2.34M |
| Income Tax Expenses | -200.00 | -500.00 | -129.10K | -129.10K | -127.70K |
| Earnings from Continuing Operations | -55.21 | -1.67 | -1.82 | -1.82 | -2.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.21M | -1.67M | -1.82M | -1.82M | -2.21M |
| EBIT | -53.89M | -1.19M | -1.41M | -1.54M | -1.49M |
| EBITDA | -53.89M | -1.18M | -1.41M | -1.54M | -1.49M |
| EPS Basic | -44.73 | -32.23 | -- | -- | -- |
| Normalized Basic EPS | -26.96 | -19.27 | -- | -- | -- |
| EPS Diluted | -44.73 | -32.23 | -- | -- | -- |
| Normalized Diluted EPS | -26.96 | -19.27 | -- | -- | -- |
| Average Basic Shares Outstanding | 4.34M | 13.30K | -- | -- | -- |
| Average Diluted Shares Outstanding | 4.34M | 13.30K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |